Portland Press, Clinical Science, 6(99), p. 511-516, 2000
DOI: 10.1042/cs0990511
Portland Press, Clinical Science, 6(99), p. 511
DOI: 10.1042/cs20000116
Full text: Unavailable
Conjugated linoleic acid (CLA) has been shown in experimental studies to have chemoprotective properties, and may decrease the deposition of body fat. CLA is prone to oxidation, and it has been suggested that increased lipid oxidation may contribute to the anti-tumorigenic effects of this agent. The present study investigates the urinary levels of 8-iso-prostaglandin F2α (8-iso-PGF2α), a major isoprostane, and of 15-oxo-dihydro-PGF2α, a major metabolite of PGF2α, as indicators of non-enzymic and enzymic arachidonic acid oxidation respectively after dietary supplementation with CLA in middle-aged men (mean age 53 years) with abdominal obesity for 1 month in a randomized controlled trial. Significant increases in the levels of both 8-iso-PGF2α and 15-oxo-dihydro-PGF2α in urine (P < 0.0001 and P = 0.0013 respectively) were observed after 1 month of daily CLA intake (4.2 g/day) as compared with the control group. The lipid peroxidation parameters had returned to their basal levels at 2 weeks after the cessation of CLA intake, and remained at the same levels for a further 2 weeks until the end of the study. CLA had no effect on serum α-tocopherol and γ-tocopherol levels, or on the urinary levels of 2,3-dinor-thromboxane B2. Thus CLA may induce both non-enzymic and enzymic lipid peroxidation in vivo in middle-aged men with abdominal obesity, without any side effects. The consequences of the increased lipid peroxidation after CLA supplementation are unknown.